Our priorities


Financing innovation


__


Plan for growth in line with public health needs and adapt financing methods to accommodate the expected wave of therapeutic innovations. Thus, repositioning France as a leader in Europe 


• Set budgetary objectives that are both multi-year (introducing a tri-annualization principle) to guarantee visibility for companies, and sufficient to allow the financing of therapeutic innovations

• Financing the health care system through a policy of controlling health care spending that includes greater penetration of generic drugs, dynamic management of the reimbursed health care basket, partial "payback" of savings from drugs, and complementary sources of financing

• Align with innovation financing methods comparable to those of the major European countries.


Early access

Reposition France as a leader in clinical research
and patient access to therapeutic innovations

• Simplify the Temporary Use Authorization (ATU) system, in particular in terms of care, in order to restore the system's attractiveness and its capacity for early access to promising therapeutic solutions for French patients, while remaining within a medically and fiscally controlled framework.
• Review the other specific mechanisms (Temporary Use Recommendation (RTU), accelerated clinical trial authorization device (Fast Track), post-Marketing Authorization (AMM)) on the same model.
• Simplify and speed up procedures for authorizing clinical trials, in order to return to the level of countries like Germany and the United Kingdom.
• Encourage the authorities and laboratories to shorten the deadlines after the Marketing Authorization (MA), starting by respecting the European standard of 180 days for evaluation and price and reimbursement decisions.

Assessment

Adapt and streamline procedures throughout the lifecycle of treatments,
to meet the new challenges of therapeutic innovation

• Restart, through a dialogue with the authorities, the work on the evaluation reform to reduce access times and set up criteria adapted to current developments and challenges of innovation (conditional evaluation, live data quality of life and patient feedback, comparators, rare diseases, etc.)
• Explain the new modes of drug development and the challenges related to therapeutic innovations, current and future.
• Ensure sustainability and equal access for all medicines throughout the country, avoiding breaks in the care pathways.

Conventional policy

Restoring meaning to conventional policy,
in particular by valuing the value brought by industry and drugs

• Engage in a comprehensive and coherent drug policy in terms of attractiveness - for production as well as research - and support for innovation.
• Promote a State / industry dialogue based on predictability and sincerity (ex: avoid large overruns of savings targets on the drug).
• Streamline relations between the Economic Committee for Health Products (CEPS) and laboratories, in particular by avoiding unnecessary negotiation stages.
• Review the specific taxation of the sector and reform the burden reduction systems (ex: Tax credit for competitiveness and employment (CICE)), in order to continue to reduce the still significant gap with countries like Germany.
• Ensure the implementation of the provisions adopted by the State within the framework of the Strategic Council for the Health Industries (CSIS) for the improvement of the attractiveness of France in life sciences and access to treatments.
Share by: